

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
THERAPEUTIC STUDIES ONLY (TXCA=Y)
40% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	1558	586	38%	1465	-93	1238	-320
ERLYTX	76	91	120%	227	151	152	76
GI	476	73	15%	182	-293	199	-277
GU	450	204	45%	510	60	673	223
GYN	57	0	0%	0	-57	0	-57
LEUK	150	40	27%	100	-50	93	-57
LUNG	524	140	27%	350	-174	340	-184
LYMPH	172	3	2%	7	-164	17	-155
MELAN	55	481	875%	1202	1147	1016	961
MMYEL	147	31	21%	77	-69	87	-60
OTHER	0	12		30	30	32	32
Total	3665	1661		4150	488	3847	182

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
NON-THERAPEUTIC STUDIES ONLY (TXCA=N)
40% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	37	4	11%	10	-27	11	-26
Breast	0	3		7	7	3	3
CCD	0	656		1640	1640	1628	1628
GI	0	2		5	5	2	2
GU	0	0		0	0	0	0
LEUK	69	2	3%	5	-64	3	-66
LUNG	43	231	537%	577	534	694	651
LYMPH	53	0	0%	0	-53	0	-53
MMYEL	92	0	0%	0	-92	0	-92
OTHER	0	11		27	27	12	12
PREV	0	29		72	72	60	60
SURV	0	27		67	67	54	54
<u>SXQOL</u>	<u>878</u>	<u>10</u>	<u>1%</u>	<u>25</u>	<u>-853</u>	<u>58</u>	<u>-820</u>
Total	1172	975		2435	1263	2525	1353

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
ALL ACCRUAL REGISTRATIONS
40% of Calendar Year is Past

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
	0	2		5	5	2	2
BREAST	1595	590	37%	1475	-120	1249	-346
Breast	0	3		7	7	3	3
CCD	0	656		1640	1640	1628	1628
ERLYTX	76	91	120%	227	151	152	76
GI	476	75	16%	187	-288	201	-275
GU	450	204	45%	510	60	673	223
GYN	57	0	0%	0	-57	0	-57
LEUK	219	42	19%	105	-114	96	-123
LUNG	567	371	65%	927	360	1034	467
LYMPH	225	3	1%	7	-217	17	-208
MELAN	55	481	875%	1202	1147	1016	961
MMYEL	239	31	13%	77	-161	87	-152
OTHER	0	23		57	57	44	44
PREV	0	29		72	72	60	60
SURV	0	27		67	67	54	54
SXQOL	878	10	1%	25	-853	58	-820
Total	4837	2638		6590	1756	6374	1537

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)
40% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	1012	246	24%	615	-397	451	-561
ERLYTX	76	71	93%	177	101	132	56
GI	418	61	15%	152	-265	164	-254
GU	375	141	38%	352	-22	445	70
GYN	57	0	0%	0	-57	0	-57
LEUK	122	30	25%	75	-47	79	-43
LUNG	441	97	22%	242	-198	215	-226
LYMPH	129	3	2%	7	-121	17	-112
MELAN	55	267	485%	667	612	551	496
MMYEL	85	31	36%	77	-7	84	-1
OTHER	0	12		30	30	32	32
Total	2770	959		2394	-371	2170	-600

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)
40% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	10	4	40%	10	0	11	1
Breast	0	2		5	5	2	2
CCD	0	634		1585	1585	1606	1606
GI	0	2		5	5	2	2
GU	0	0		0	0	0	0
LEUK	69	2	3%	5	-64	3	-66
LUNG	30	160	533%	400	370	406	376
LYMPH	53	0	0%	0	-53	0	-53
MMYEL	92	0	0%	0	-92	0	-92
OTHER	0	10		25	25	11	11
PREV	0	22		55	55	44	44
SURV	0	21		52	52	35	35
<u>SXQOL</u>	<u>740</u>	<u>10</u>	<u>1%</u>	<u>25</u>	<u>-715</u>	<u>58</u>	<u>-682</u>
Total	994	867		2167	1173	2178	1184

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY
40% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
	0	2		5	5	2	2
BREAST	1022	250	24%	625	-397	462	-560
Breast	0	2		5	5	2	2
CCD	0	634		1585	1585	1606	1606
ERLYTX	76	71	93%	177	101	132	56
GI	418	63	15%	157	-260	166	-252
GU	375	141	38%	352	-22	445	70
GYN	57	0	0%	0	-57	0	-57
LEUK	191	32	17%	80	-111	82	-109
LUNG	471	257	55%	642	171	621	150
LYMPH	182	3	2%	7	-174	17	-165
MELAN	55	267	485%	667	612	551	496
MMYEL	177	31	18%	77	-99	84	-93
OTHER	0	22		55	55	43	43
PREV	0	22		55	55	44	44
SURV	0	21		52	52	35	35
SXQOL	740	10	1%	25	-715	58	-682
Total	3764	1828		4566	806	4350	586

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES
40% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	65	488	751%	1220	1155	1101	1036
CCD	0	656		1640	1640	1628	1628
GI	81	13	16%	32	-48	38	-43
GU	215	22	10%	55	-160	46	-169
LEUK	0	2		5	5	12	12
LUNG	53	0	0%	0	-53	1	-52
LYMPH	7	1	14%	2	-4	9	2
MELAN	0	438		1095	1095	926	926
MMYEL	0	31		77	77	83	83
OTHER	0	15		37	37	29	29
PREV	0	29		72	72	60	60
SURV	0	27		67	67	54	54
<u>SXQOL</u>	<u>878</u>	<u>10</u>	<u>1%</u>	<u>25</u>	<u>-853</u>	<u>58</u>	<u>-820</u>
Total	1299	1732		4327	3030	4045	2746

26-MAY-2017 18:10
SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
		A221405	ALLIANCE			2			
BREAST	II	A011203 Breast, Adv, Tam vs Endoxifen	ALLIANCE	27JAN2015:00:00:00		7		0.2	
		S1416 Brst, TNBC/BRCA, Cis+/- ABT-888	SWOG	07JUL2016:00:00:00	10	86	333	12.8	Dec-2018
	III	A011106 Breast, Neoadj, ALTERNATE study	ALLIANCE	15FEB2014:00:00:00		38		1.7	
		A011202 Breast, Nodal XRT +/- ALND	ALLIANCE			49			
		A011401 Breast, adj, Stage II/III HER2-, weight loss	ALLIANCE	29AUG2016:00:00:00		37		5.5	
		B51 Breast, Regional Nodal XRT	NRG			13			
		B55 Brst, Adj Olaparib for BRCA, TNBC	NRG	03JUL2014:00:00:00		15		0.8	
		E2112 Brst, Adv, Exemestane +/- Entinostat	ECOG-ACR	02JAN2014:00:00:00		32		1.3	
		NRGBR003 Brst, Adj, TNBC, AC -> WP +/- Carbo	NRG	22JAN2015:00:00:00		34		1.8	
		S1007 Breast, Adj, N1, Endocrine +/- Chemo	SWOG	15JAN2011:00:00:00	76	4895	4000	42.7	Sep-2015
		S1207 Brst, Adj, Endocrine +/- Everolimus	SWOG	03SEP2013:00:00:00	44	1230	1900	37.5	Oct-2018
		S1222 Brst, Fulv. +/- Ever. +/- Anastr.	SWOG	09MAY2014:00:00:00		37	840		Feb-2015 Temp Close
		S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	SWOG	15NOV2016:00:00:00	6	24	1000	4.0	> 15 Yrs
	OTHER	E1Z11 Brst, Genetic Predictors of AIMSS	ECOG-ACRIN	10MAY2013:00:00:00		142		0.7	
Breast	III	A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	ALLIANCE	08DEC2016:00:00:00		3		0.5	
CCD	III	A011104 Preoperative Breast MRI	ALLIANCE	21FEB2014:00:00:00		8		0.5	
		S1415CD TrACER CSF Standing Order Intervention for FN	SWOG	01SEP2016:00:00:00	8	448	3960	72.3	May-2021
	OTHER	S1417CD Colorectal, Cost Cohort Study	SWOG	13MAY2016:00:00:00	12	55	374	7.3	Dec-2020
ERLYTX	II	A071401 Prog Meningiomas, SMO/AKT/NF2 Inhib	ALLIANCE	06AUG2015:00:00:00		5		0.2	
		S1609 Rare Tumor, Comb Nivo/Ipi	SWOG	13JAN2017:00:00:00	4	53	334	11.9	Apr-2019
	II-III	A071102 GBM, adj TMZ +/- Veliparib	ALLIANCE	19SEP2014:00:00:00		37		0.8	
		ARST1321 NonRhabdo STS, Pazopanib (PAZNTIS)	COG	16MAY2014:00:00:00		3		0.2	
	OTHER	EAY131 MATCH	ECOG-ACR	12AUG2015:00:00:00		82		7.7	
GI	I-II	S1313 Panc, Met, mFolfinirox +/- PEGPH20	SWOG	06JAN2014:00:00:00		126	172		Mar-2017 Temp Close
	II	A021501 Adeno Panc, Borderline Resect, Chemo vs ChemoRT	ALLIANCE	01DEC2016:00:00:00		1		0.2	
		E7208 CRC, Adv, Irino/Cet +/- Ramucirumab	ECOG-ACRIN	20FEB2014:00:00:00		22		0.7	
		EA2133 Anal, local recur/met, Cis+5FU vs Taxol/Carbo	ECOG-ACRIN	29JAN2016:00:00:00		1		0.2	
		EA2142 GI NEC, Adv G3, EP vs TMZ + CAP	ECOG-ACRIN	06NOV2015:00:00:00		1		0.0	
		NRGGI002 Rectal, Ph II, Sensitization using TNT	NRG	12OCT2016:00:00:00		2		0.3	
		S1505 Panc, Resect, Perioperative Chemo	SWOG	12OCT2015:00:00:00	19	79	112	0.0	> 15 Yrs
		S1513 Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888	SWOG	01SEP2016:00:00:00	8	40	143	6.3	Sep-2018
	II-III	N1048 Rectal, Local Adv, ChemoRT +/- FOLFOX	ALLIANCE	13JAN2012:00:00:00		117		2.7	
	III	R0848 Panc, Adj, Erlotinib v ChemoRT	NRG	01MAR2014:00:00:00		20		0.0	
GU	II	EA8141 UTUC, HG, Chemo then Surg	ECOG-ACR	27JAN2015:00:00:00		8		0.3	

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
		S1314 Blad, COXEN Neoadj. Chemo + Cyst	SWOG	11JUL2014:00:00:00	34	193	230	7.5	Sep-2017
		S1500 pRCC,Adv, Sunitinib vs MET inhib	SWOG	05APR2016:00:00:00	13	39	180	4.2	Feb-2020
		S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab	SWOG	07FEB2017:00:00:00	3	3	148	0.8	Dec-2031
	III	A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	ALLIANCE	01JUL2015:00:00:00		2		0.2	
		E2810 Renal, Pazopanib vs Placebo	ECOG-ACRIN	17APR2012:00:00:00		46		0.3	
		R0924 Pros, NADT+WPRT vs. NADT+P&SV RT	NRG	07JUL2011:00:00:00		45		2.8	
		S1216 Pros Adv, ADT +/- TAK-700 or Bic	SWOG	01MAR2013:00:00:00	50	1272	1304	20.2	Jun-2017
		S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	SWOG	07FEB2017:00:00:00	3	9	969	2.5	> 15 Yrs
LEUK	I	S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP	SWOG	01APR2014:00:00:00	37	35	38	0.8	Aug-2017
	I-II	S1318 ALL, Age 65+, Ph±, Blinatumomab	SWOG	12JAN2015:00:00:00	28	40	44	3.5	Jun-2017
	II	S0919 Rel AML: Pravastatin+Ida+Ara-C	SWOG	15AUG2009:00:00:00	93	115	110	0.2	Dec-2014
	III	E1910 BCR-ABL-neg, B ALL, Blinatumomab	ECOG-ACRIN	23DEC2013:00:00:00		60		3.0	
		E2906 AML, Age 60+, Clo vs Dauno+Cy	ECOG-ACRIN	24FEB2011:00:00:00		75		0.0	
	OTHER	NHLBIMDS LEUK, National MDS Study	ECOG-ACRIN	05APR2016:00:00:00		3		0.5	
LUNG	I-II	8811 NSCLC, Stage III,ChemoRT+ABT-888	SWOG	02JAN2013:00:00:00	52	42	162	3.0	Aug-2020
	II	R1306 NSCLC,Adv,ALK/EGFR,TargetAgents	NRG	04NOV2013:00:00:00		8		0.0	
		S1400G HRRD: Talazoparib (BMN 673)	SWOG	07FEB2017:00:00:00	3	12	60	3.3	Jul-2018
		S1507 NSCLC, Adv, Kras Mut, Trametinib + Docetaxel	SWOG	18JUL2016:00:00:00	10	30	53	4.2	Oct-2017
	II-III	NRGCC003 SCLC, PCI or HA-PCI	NRG	07DEC2015:00:00:00		1		0.0	
		S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab	SWOG	25MAR2015:00:00:00	26	111	605	6.0	Mar-2024
	III	A081105 ALCHEMIST1, EGFR mut, Erlotinib	ALLIANCE	02JAN2014:00:00:00		22		1.7	
		C140503 NSCL, Lobect v Sublobar resect	ALLIANCE	09JUL2007:00:00:00		27		0.0	
		C30607 NSCL,Adv Main Sunitinib v Placbo	ALLIANCE			2			
		C30610 SCLC, Thoracic RT	ALLIANCE	21MAR2008:00:00:00		50		0.0	
		E4512 ALCHEMIST2, ALK mut, Crizotinib	ECOG-ACR	18AUG2014:00:00:00		3		0.0	
		EA5142 ALCHEMIST3, Non-match, Nivolumab	ECOG-ACRIN	16MAY2016:00:00:00		12		1.2	
		S1400I Non-Match: Nivo + Ipi vs Nivo	SWOG	18DEC2015:00:00:00	17	200	350	10.3	Jul-2018
	OTHER	A151216 ALCHEMIST0 - screening	ALLIANCE	06FEB2014:00:00:00		286		15.5	
		S1400 SCCA,Adv, Biomarker Master	SWOG	15JUN2014:00:00:00	35	1281		31.2	
LYMPH	III	A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo	ALLIANCE	15JUL2016:00:00:00		1		0.2	
MELAN	II	E3612 MELAN,Adv Ipilimumab±Bevacizumab	ECOG-ACR			5			
		S1320 Adv, BRAF mut, Inter v Contin	SWOG	22JUL2014:00:00:00	34	152	280	4.8	Jul-2019
		S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro)	SWOG	20OCT2016:00:00:00	7	1	77	0.2	> 15 Yrs
	II-III	EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim	ECOG-ACRIN	01MAR2016:00:00:00		30		2.8	
	III	EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	ECOG-ACR	15DEC2015:00:00:00		16		0.8	

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
		S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475	SWOG	15OCT2015:00:00:00	19	1043	1378	86.7	Aug-2017
MMYEL	I-II	S1211 MM,High Risk, RVD+/-ELO	SWOG	27OCT2012:00:00:00		142	110		Jun-2016 Temp Close
	III	E1A11 MM, frontline, BLD vs CLD	ECOG-ACRIN	22NOV2013:00:00:00		117		7.2	
		E3A06 AMM, Lenalidomide vs Observation	ECOG-ACRIN	08NOV2010:00:00:00		34		0.3	
OTHER	I-II	A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II	ALLIANCE	26JAN2015:00:00:00		3		0.2	
	II	A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo	ALLIANCE	02SEP2014:00:00:00		1		0.0	
		A091305 HN, Adv, Thyroid PPAR agonist + Chemo	ALLIANCE	01SEP2014:00:00:00		2		0.3	
		A091401 Sarc,	ALLIANCE	18JUN2015:00:00:00		5		0.0	
		A091404 HN, AR+, Enzalutamide	ALLIANCE	25SEP2015:00:00:00		2		0.3	
		AOST1521 Osteo CDX-011 in Rec/Ref Dz,Ph 2	COG	02JUL2015:00:00:00		3		0.0	
		E3311 Oroph,Srg + Low or Std IMRT	ECOG-ACRIN	01MAR2014:00:00:00		36		0.2	
		EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp	ECOG-ACRIN	29MAR2016:00:00:00		1		0.2	
		NRGBN001 HN, novel vs. std chemoradiation + chemo	NRG	28AUG2015:00:00:00		1		0.2	
		NRGHN002 HN, Adv, Orophyx RT vs RT+ Chemo	NRG	27OCT2014:00:00:00		1		0.0	
	II-III	G0281 Ovar, Recur/prog LG, IC chemo vs trametinib	NRG	27FEB2014:00:00:00		1		0.2	
		G0286B Adv Endometrial,Metformin/Chemo	NRG			1			
		NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care	NRG	06FEB2016:00:00:00		3		0.3	
		NRGHN001 Nasopharyngeal , Individual Tx EBV	NRG	21APR2014:00:00:00		3		0.2	
		R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux	NRG	18MAR2013:00:00:00		3		0.0	
	III	N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC	ALLIANCE			4			
		NRGGY004 Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo	NRG	04FEB2016:00:00:00		4		0.3	
		R0724 Cervical, Chem+RT +/- Adj. Chemo	NRG	15JAN2014:00:00:00		1		0.0	
		R0920 HN, Adv, Postop IMRT ± Cetuximab	NRG	24DEC2013:00:00:00		10		0.2	
	OTHER	EAQ152 Communication & education in tumor profiling	ECOG-ACR	26SEP2016:00:00:00		11		1.8	
PREV	III	A211102 Breast, Atypia via RPFNA, Metformin v Placebo	ALLIANCE	01FEB2015:00:00:00		3		0.2	
		S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac	SWOG	01MAR2013:00:00:00	50	147	480	6.2	Oct-2021
	OTHER	A211201 Breast Density, MA.32 companion	ALLIANCE	22AUG2012:00:00:00		14		0.0	
SURV	III	E1Q11 EROS: Reproductive Health in Cancer Survivors	ECOG-ACR	30SEP2015:00:00:00		4		0.7	
	OTHER	S1316 Compar. Effectiv. Trial for MBO	SWOG	09MAR2015:00:00:00	26	79	200	4.5	Jul-2019
SXQOL	III	A221101 Glioma, Nuvigil/Placebo Fatigue	ALLIANCE	03JUN2013:00:00:00		15		0.3	
		A221102 Brst,AI Arthralgia,Testosterone	ALLIANCE	07SEP2012:00:00:00		10		0.5	

Accrual goals assume studies are not terminated early as a result of interim analysis.

Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.

Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.

Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA Cntrl Study	Temp Close
OTHER	BREAST	Y	ECOG-ACRIN	E1Z11 Brst,Genetic Predictors of AIMSS	E1Z11	Y	
	CCD	N		S1417CD Colorectal, Cost Cohort Study		Y	
	ERLYTX	Y	ECOG-ACR	EAY131 MATCH	EAY131	N	
	LEUK	Y	ECOG-ACRIN	NHLBIMDS LEUK, National MDS Study	NHLBI-MDS	Y	
	LUNG	Y	SWOG	S1400 SCCA,Adv, Biomarker Master	S1400	N	
		Y	ALLIANCE	A151216 ALCHEMIST0 - screening	A151216	N	
	OTHER	Y	ECOG-ACR	EAQ152 Communication & education in tumor profiling	EAQ152	Y	
	PREV	Y	ALLIANCE	A211201 Breast Density, MA.32 companion	A211201	Y	
	SURV	Y	SWOG	S1316 Compar. Effectiv. Trial for MBO	S1316	Y	
I	LEUK	N		S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP		N	
II	GI	N		S1313 Panc, Met, mFolirinox+/-PEGPH20		N	Y
	LEUK	Y	SWOG	S1318 ALL, Age 65+, Ph±, Blinatumomab	S1318	N	
	LUNG	N		8811 NSCLC, Stage III, ChemoRT+ABT-888		N	
	MMYEL	Y	SWOG	S1211 MM, High Risk, RVD+/-ELO	S1211	N	Y
	OTHER	Y	ALLIANCE	A091304 Adv Sarc, MLN0128 v Pazopanib, Ph/II	A091304	N	
II	BREAST	Y	SWOG	S1416 Brst, TNBC/BRCA, Cis+/- ABT-888	S1416	N	
		Y	ALLIANCE	A011203 Breast, Adv, Tam vs Endoxifen	A011203	N	
	ERLYTX	Y	SWOG	S1609 Rare Tumor, Comb Nivo/Ipi	S1609	N	
		Y	ALLIANCE	A071401 Prog Meningiomas, SMO/AKT/NF2 Inhib	A071401	N	
	GI	Y	SWOG	S1513 Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888	S1513	N	
		Y	SWOG	S1505 Panc, Resect, Perioperative Chemo	S1505	N	
		Y	ECOG-ACRIN	E7208 CRC, Adv, Irino/Cet+/-Ramucirumab	E7208	N	
		Y	ECOG-ACRIN	EA2142 GI NEC, Adv G3, EP vs TMZ + CAP	EA2142	N	
		Y	NRG	NRGGI002 Rectal, Ph II, Sensitization using TNT	NRG-GI002	N	
		Y	ALLIANCE	A021501 Adeno Panc, Borderline Resect, Chemo vs ChemoRT	A021501	Y	
		Y	ECOG-ACRIN	EA2133 Anal, local recur/met, Cis+5FU vs Taxol/Carbo	EA2133	Y	
	GU	Y	SWOG	S1314 Blad, COXEN Neoadj. Chemo + Cyst	S1314	N	
		Y	SWOG	S1500 pRCC, Adv, Sunitinib vs MET inhib	S1500	N	
		Y	SWOG	S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab	S1605	N	
		Y	ECOG-ACR	EA8141 UTUC, HG, Chemo then Surg	EA8141	N	
	LEUK	N		S0919 Rel AML: Pravastatin+Ida+Ara-C		N	
	LUNG	Y	SWOG	S1400G HRRD: Talazoparib (BMN 673)	S1400G	N	
		Y	SWOG	S1507 NSCLC, Adv, Kras Mut, Trametinib + Docetaxel	S1507	N	
		Y	NRG	R1306 NSCLC, Adv, ALK/EGFR, TargetAgents	RTOG-1306	N	
	MELAN	Y	SWOG	S1320 Adv, BRAF mut, Inter v Contin	S1320	N	
		Y	SWOG	S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro)	S1512	N	
		Y	ECOG-ACR	E3612 MELAN, Adv Ipilimumab±Bevacizumab	E3612	N	

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA Cntrl Study	Temp Close
	OTHER	Y	ECOG-ACRIN	E3311 Oroph,Srg + Low or Std IMRT	E3311	Y	
		Y	NRG	NRGBN001 HN, novel vs. std chemoradiation + chemo	NRG-BN001	N	
		Y	COG	AOST1521 Osteo CDX-011 in Rec/Ref Dz,Ph 2	AOST1521	N	
		Y	ALLIANCE	A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo	A091202	N	
		Y	ALLIANCE	A091401 Sarc,	A091401	N	
		Y	ALLIANCE	A091305 HN, Adv, Thyroid PPAR agonist + Chemo	A091305	N	
		Y	ALLIANCE	A091404 HN, AR+, Enzalutamide	A091404	N	
		Y	ECOG-ACRIN	EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp	EA3132	N	
		Y	NRG	NRGHN002 HN, Adv, Orophyx RT vs RT+ Chemo	NRG-HN002	Y	
II-III	ERLYTX	Y	ALLIANCE	A071102 GBM, adj TMZ +/- Veliparib	A071102	N	
		Y	COG	ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS)	ARST1321	N	
	GI	Y	ALLIANCE	N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX	N1048	Y	
	LUNG	Y	SWOG	S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab	S1403	N	
		Y	NRG	NRGCC003 SCLC, PCI or HA-PCI	NRG-CC003	Y	
	MELAN	Y	ECOG-ACRIN	EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim	EA6141	N	
	OTHER	Y	NRG	NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care	NRG-GY005	Y	
		Y	NRG	G0286B Adv Endometrial,Metformin/Chemo	GOG-0286B	Y	
		Y	NRG	R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux	RTOG-1216	Y	
		Y	NRG	NRGHN001 Nasopharyngeal , Individual Tx EBV	NRG-HN001	Y	
		Y	NRG	G0281 Ovar, Recur/prog LG, IC chemo vs trametinib	GOG-0281	Y	
III	BREAST	N		S1222 Brst,Fulv. +/- Ever. +/- Anastr.		N	Y
		Y	SWOG	S1207 Brst,Adj,Endocrine+/-Everolimus	S1207	Y	
		Y	SWOG	S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	S1418	Y	
		Y	SWOG	S1007 Breast,Adj,N1,Endocrine+/-Chemo	S1007	Y	
		Y	ALLIANCE	A011202 Breast, Nodal XRT +/- ALND	A011202		
		Y	ALLIANCE	A011106 Breast, Neoadj, ALTERNATE study	A011106	N	
		Y	NRG	B51 Breast, Regional Nodal XRT	NSABP-B-51	Y	
		Y	ALLIANCE	A011401 Breast, adj, Stage II/III HER2-, weight loss	A011401	Y	
		Y	NRG	NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo	NRG-BR003	N	
		Y	ECOG-ACR	E2112 Brst,Adv,Exemestane+/-Entinostat	E2112	Y	
		Y	NRG	B55 Brst, Adj Olaparib for BRCA,TNBC	NSABP-B-55	Y	
	Breast	Y	ALLIANCE	A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	A011502	N	
	CCD	Y	SWOG	S1415CD TrACER CSF Standing Order Intervention for FN	S1415CD	Y	
		Y	ALLIANCE	A011104 Preoperative Breast MRI	A011104	Y	
	GI	Y	NRG	R0848 Panc, Adj, Erlotinib v ChemoRT	RTOG-0848	Y	
	GU	Y	SWOG	S1216 Pros Adv, ADT +/- TAK-700 or Bic	S1216	N	
		Y	SWOG	S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	S1602	Y	

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

<u>Phase</u>	<u>Comm.</u>	<u>Int grp</u>	<u>Stat Center</u>	<u>Study</u>	<u>NCIPROTO</u>	<u>CA Cntrl Study</u>	<u>Temp Close</u>
		Y	ECOG-ACRIN	E2810 Renal, Pazopanib vs Placebo	E2810	Y	
		Y	NRG	R0924 Pros, NADT+WPRT vs. NADT+P&SV RT	RTOG-0924	Y	
		Y	ALLIANCE	A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	A031102	Y	
LEUK		Y	ECOG-ACRIN	E2906 AML, Age 60+, Clo vs Dauno+Cy	E2906	Y	
		Y	ECOG-ACRIN	E1910 BCR-ABL-neg, B ALL, Blinatumomab	E1910	N	
LUNG		Y	SWOG	S1400I Non-Match: Nivo + Ipi vs Nivo	S1400I	N	
		Y	ALLIANCE	C30610 SCLC, Thoracic RT	CALGB-30610	Y	
		Y	ALLIANCE	C30607 NSCL, Adv Main Sunitinib v Placbo	CALGB-30607	Y	
		Y	ALLIANCE	C140503 NSCL, Lobect v Sublobar resect	CALGB-140503		
		Y	ALLIANCE	A081105 ALCHEMIST1, EGFR mut, Erlotinib	A081105	N	
		Y	ECOG-ACRIN	EA5142 ALCHEMIST3, Non-match, Nivolumab	EA5142	N	
		Y	ECOG-ACR	E4512 ALCHEMIST2, ALK mut, Crizotinib	E4512	N	
LYMPH		Y	ALLIANCE	A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo	A051301	N	
MELAN		Y	SWOG	S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475	S1404	Y	
		Y	ECOG-ACR	EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	EA6134	Y	
MMYEL		Y	ECOG-ACRIN	E3A06 AMM, Lenalidomide vs Observation	E3A06	Y	
		Y	ECOG-ACRIN	E1A11 MM, frontline, BLD vs CLD	E1A11	Y	
OTHER		Y	NRG	R0920 HN, Adv, Postop IMRT ± Cetuximab	RTOG-0920	Y	
		Y	ALLIANCE	N0577 BRN, Glio, Tem vs Tem+RT vs RT+PVC	N0577	N	
		Y	NRG	R0724 Cervical, Chem+RT +/- Adj. Chemo	RTOG-0724	Y	
		Y	NRG	NRGGY004 Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo	NRG-GY004	Y	
PREV		Y	SWOG	S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac	S0820	Y	
		Y	ALLIANCE	A211102 Breast, Atypia via RPFNA, Metformin v Placebo	A211102	Y	
SURV		Y	ECOG-ACR	E1Q11 EROS: Reproductive Health in Cancer Survivors	E1Q11	Y	
SXQOL		Y	ALLIANCE	A221101 Glioma, Nuvigil/Placebo Fatigue	A221101	Y	
		Y	ALLIANCE	A221102 Brst, AI Arthralgia, Testosterone	A221102	Y	
		Y	ALLIANCE	A221405	A221405		

**PHASE III SWOG COORDINATED OPEN STUDIES
SORTED BY STUDY ID**

Protocol Number	Study	Accrual Goal	Open Stat/Date	Months Open	Accrual as of 01Jan02	Current Accrual	Proj. Annual Accr. Rate	EXPCLOSE	Proj. Study Duration (Years)
S0820 S0820	PACES: ColrecStg0-3 Blind DFMO/Sulindac (PREV)	480	Y-03/01/13	50	147	147	74	Oct-2021	8.7
S1007 S1007	Breast,Adj,N1,Endocrine+/-Chemo (BREAST)	4000	Y-01/15/11	76	4895	4895	512	Sep-2015	4.7
S1207 S1207	Brst,Adj,Endocrine+/-Everolimus (BREAST)	1900	Y-09/03/13	44	1230	1230	450	Oct-2018	5.1
S1216 S1216	Pros Adv, ADT +/- TAK-700 or Bic (GU)	1304	Y-03/01/13	50	1272	1272	242	Jun-2017	4.3
S1222	Brst,Fulv. +/- Ever. +/- Anastr. (BREAST)	840	T-05/09/14	36	37	37	0	> 15 Yrs	> 15 Yrs
S1400I S1400I	Non-Match: Nivo + Ipi vs Nivo (LUNG)	350	Y-12/18/15	17	200	200	124	Jul-2018	2.6
S1403 S1403	Adv,EGFR-mt,Afatinib+/-Cetuximab (LUNG)	605	Y-03/25/15	26	111	111	72	Mar-2024	9.0
S1404 S1404	Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 (MELAN)	1378	Y-10/15/15	19	1043	1043	1040	Aug-2017	1.9
S1415CD S1415CD	TrACER CSF Standing Order Intervention for FN (CCD)	3960	Y-09/01/16	8	448	448	868	May-2021	4.7
S1418 S1418	Breast, Adj, TNBC, MK-3475 (Pembrolizumab) (BREAST)	1000	Y-11/15/16	6	24	24	48	> 15 Yrs	> 15 Yrs
S1602 S1602	Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG (GU)	969	Y-02/07/17	3	9	9	29.692078	> 15 Yrs	> 15 Yrs

Accrual goals assume studies are not terminated early as a result of interim analysis.

Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.

Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.

Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.